
Aldeyra Therapeutics fell 87.0% from $4.95 to $0.64, behind the S&P 500's +13.3%. Its worst day was Mar 17 (−70.7%), and its low came Oct 30 at $0.56.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Aldeyra Therapeutics shares rose 33.1%, while the S&P 500 fell 0.3%.
+33.1%, the year's best day · S&P 500 −0.3%
Story events cover the past 12 months · Times ET
EPS of $-0.10 beat the $-0.12 estimate on $0.00 revenue (est. $24.3M).
+2.9% · S&P 500 +0.1%
Aldeyra Therapeutics shares fell 70.7%, while the S&P 500 rose 0.3%.
−70.7%, the year's worst day, on 53M shares, the year's heaviest volume · S&P 500 +0.3%
EPS of $-0.06 beat the $-0.12 estimate on $0.00 revenue (est. $47.0M).
0.0% · S&P 500 +0.8%
EPS of $-0.09 missed the $-0.08 estimate on $0.00 revenue (est. $47.0M).
−2.5% · S&P 500 +0.6%
Aldeyra Therapeutics shares fell 21.1%, while the S&P 500 rose 0.7%.
−21.1% · S&P 500 +0.7%
Aldeyra Therapeutics closed at its lowest level of the year, 88.7% below where the year started.
−15.0% · S&P 500 −1.8%
Where it ended: a close of $0.64 on Nov 13, 2026. Up next: Q3 2026 earnings on Nov 27, 2026 (EPS est. $-0.10, revenue est. $1.0M).
Nothing in the past 12 months.
All ALDX dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ALDX and SPY from Benzinga historical bars. Not investment advice.